Abstract
The idea that within the bulk of leukemic cells there are immature progenitors which are intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not recent. Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status. LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity. In addition, unique features regarding the interaction of these cells with the microenvironment have been characterized. Therapeutic strategies targeting these unique features are at different stages of development but the reported results are promising. The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
Keywords: Leukemia stem cells, acute myeloid leukemia, bone marrow microenvironment
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting the Acute Myeloid Leukemia Stem Cells
Volume: 10 Issue: 2
Author(s): Alexandre Krause, Luciana M. Fontanari Krause and Eduardo M. Rego
Affiliation:
Keywords: Leukemia stem cells, acute myeloid leukemia, bone marrow microenvironment
Abstract: The idea that within the bulk of leukemic cells there are immature progenitors which are intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not recent. Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status. LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity. In addition, unique features regarding the interaction of these cells with the microenvironment have been characterized. Therapeutic strategies targeting these unique features are at different stages of development but the reported results are promising. The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
Export Options
About this article
Cite this article as:
Krause Alexandre, Fontanari Krause M. Luciana and Rego M. Eduardo, Targeting the Acute Myeloid Leukemia Stem Cells, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909281
DOI https://dx.doi.org/10.2174/187152010790909281 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets A Comprehensive Review on Pharmacological Properties of Abrus precatorius L.
The Natural Products Journal Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry RNA Interference as A Gene-Specific Approach for Molecular Medicine
Current Medicinal Chemistry Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry n-3 Polyunsaturated Fatty Acids and the Prevention of Colorectal Cancer: Molecular Mechanisms Involved
Current Medicinal Chemistry Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Melatonin a Promising Candidate for DNA Double-Stranded Breaks Reduction in Patients Undergoing Abdomen-Pelvis Computed Tomography Examinations
Anti-Cancer Agents in Medicinal Chemistry Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
Current Cancer Drug Targets Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology